Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume 13, Issue 5, Pages 699-715Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14656566.2012.667803
Keywords
adverse effect profiles; drug-drug interactions; efficacy profiles; eslicarbazepine acetate; lacosamide; novel mechanisms of action; pharmacokinetics; retigabine; therapeutic drug monitoring; third-generation antiepileptic drugs
Categories
Funding
- Eisai
- GlaxoSmithKline
- Johnson and Johnson
- Novartis
- Pfizer
- Sanofi-Aventis
- UCB Pharma
- Department of Health's NIHR
Ask authors/readers for more resources
Introduction: The search for new, more effective antiepileptic drugs (AEDs) continues. The three most recently approved drugs, the so-called third-generation AEDs, include lacosamide, retigabine and eslicarbazepine acetate and are licensed as adjunctive treatment of partial epilepsy in adults. Areas covered: For the above three AEDs, their mechanisms of action, pharmacokinetic characteristics, drug-drug interactions, pharmacotherapeutics, dose and administration and therapeutic drug monitoring are reviewed in this paper. Expert opinion: Lacosamide and retigabine act through novel mechanisms, while eslicarbazepine acetate, a pro-drug for eslicarbazepine, acts in a similar manner to several other AEDs. All three AEDs are associated with linear pharmacokinetic and rapid absorption and undergo metabolism. Their drug-drug interaction profile is low (lacosamide and retigabine) to modest (eslicarbazepine) in propensity. At the highest approved doses for the three AEDs, responder rates were similar. The most commonly observed adverse effects compared with placebo were dizziness, headache, diplopia and nausea for lacosamide; dizziness, somnolence and fatigue for retigabine and dizziness and somnolence for eslicarbazepine acetate. The precise role that these new AEDs will have in the treatment of epilepsy and whether they will make a significant impact on the prognosis of intractable epilepsy is not yet known and will have to await further clinical experience.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available